The need for longer time horizons for cost-utility evaluation in bullous pemphigoid – reply from authors

Abstract

We thank Drs Liu and Sebaratnam for their commentary on our paper¹ and agree with their insights. The adverse event legacy or oral steroids may be a long one; their concerns support our proposed strategy of sparing oral steroids by starting on doxycycline. Of patients starting on doxycycline within the BLISTER trial, 57.8% subsequently received at least one prescription of prednisolone. Thus, the two strategies may converge over time, although possibly much less prednisolone is required to achieve remission at least in the first year.

This article is protected by copyright. All rights reserved.